GGrantIndex
← Leaderboards

Andrew R Draganski

Zylo Therapeutics, Inc.

$2,678,047
Attributed
$3,387,421
Total exposure
6
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.6M · FY201925
$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$3,387,421 · 6

By mechanism

R44$1,705,226 · 1
R41$1,682,195 · 5

Top collaborators

Most similar at Zylo Therapeutics, Inc.

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Dose

Research focus

DoseTopical ApplicationFormulationSafety StudyTissuesNitric OxideSilicon DioxideQuality Of LifeAffectParticlePharmaceutical PreparationsNovel TherapeuticsFda ApprovedIn VivoPhase 1 StudyPrototypeClinical TranslationEfficacy StudyPenetrationGenerationsBaseIn VitroOperative Surgical ProceduresAging

Grant awards (9)

Development and optimization of a nitric oxide releasing microparticle formulation for the topical treatment of chronic rhinosinusitis$300,000
R41 · FY2025 · AI · contact PI
Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus.$145,888
R41 · FY2024 · AR · contact PI
Development and optimization of a nitric oxide releasing microparticle-basedtopical treatment for onychomycosis$300,000
R41 · FY2023 · AI · contact PI
Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus.$147,861
R41 · FY2023 · AR · contact PI
Development of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors$1,008,058
R44 · FY2022 · DK · contact PI
Development and optimization of a nitric oxide releasing microparticle-basedtopical treatment for onychomycosis$300,000
R41 · FY2022 · AI · contact PI
Optimization of a nanoparticle-based topical PDE5i formulation for treatment of erectile dysfunction$263,446
R41 · FY2022 · DK · contact PI
Development of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors$697,168
R44 · FY2021 · DK · contact PI
Optimization of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors$225,000
R41 · FY2019 · DK · contact PI